Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.61 |
| ▸ | KDR | P35968 | 5/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.53 |
| ▸ | FBP1 | P09467 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108631 | 1.00 | EGFR (0.61) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL5115923 | 0.92 | EGFR (0.61) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL5122677 | 0.91 | EGFR (0.61) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL5122027 | 0.90 | EGFR (0.63) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL5122127 | 0.90 | EGFR (0.63) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL5113258 | 0.90 | EGFR (0.63) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL5115969 | 0.90 | EGFR (0.61) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4966935 | 0.90 | EGFR (0.61) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5115994 | 0.90 | EGFR (0.61) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4967379 | 0.88 | EGFR (0.73) | EGFRKDRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461166-B2 | Anilinoquinazolinyl amide derivatives; radiolabels as bioprobes for Positron Emission Tomography and Single Photon Emission Computed Tomography, and as radiopharmaceuticals for radiotherapy; improved solubility, bioavailability, biostability | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2013-06-11 | — | — | US | disclosed |
| EP-1957468-A2 | POLYALKYLENE GLYCOL DERIVATIVES OF 4 - (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | T.K. Signal Ltd. (IL) | 2008-08-20 | — | — | EP | disclosed |
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | T.K. SIGNAL LTD. (IL) | 2008-03-06 | — | — | US | disclosed |
| WO-2007029251-A2 | POLYALKYLENE GLYCOL DERIVATIVES OF 4- (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GR0WTH FACT0R RECEPTOR TYROSINE KINASE | T.K. SIGNAL LTD. (IL) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | EGFR, TK1, ERBB2 | EGFR 1/4885KDR 8/4885HDAC3 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.